规范化激素补充治疗对围绝经期和绝经后女性激素水平的影响及临床效果分析  

Effect and clinical effect of Standardized hormone Supplement therapy on hormone levels of Perimenopausal and Postmenopausal women

作　　者：陈玥[1] 蔡巧娟[2] 陈蔓青[3] 张晓娜 Chen Yue;Cai Qiaojuan;Chen Manqing;Zhang Xiaona(Department of Obstetrics and Gynecology,Chaozhou Maternal and Child Health Hospital,Chaozhou 521000,China;Out-patient Department,Chaozhou Maternal and Child Health Hospital,Chaozhou 521000,Guangdong,China;Department of Breast Surgery,Chaozhou Maternal and Child Health Hospital,Chaozhou 521000,China)

机构地区：[1]潮州市妇幼保健院妇产科,广东潮州521000 [2]潮州市妇幼保健院门诊部,广东潮州521000 [3]潮州市妇幼保健院乳腺外科,广东潮州521000

出　　处：《实用妇科内分泌电子杂志》2021年第9期55-58,共4页Electronic Journal of Practical Gynecological Endocrinology

摘　　要：目的探究规范化激素补充治疗对围绝经期和绝经后女性激素水平的影响及临床效果。方法选取48例围绝经期女性给予低剂量用药治疗方案,作为低剂量组;另选取同期52例绝经后女性给予超低剂量用药治疗方案,作为超低剂量组。对比两组给药后激素水平变化、绝经相关症状评分、子宫内膜厚度及不良反应发生率。结果低剂量组和超低剂量组治疗前雌二醇(E_(2))水平分别为(123.47±55.86)pmol/L、(70.14±33.16)pmol/L,比较差异有统计学意义(P<0.05);治疗后24周,两组E_(2)水平比较差异无统计学意义(P>0.05);治疗后超低剂量组卵泡刺激素(FSH)水平显著低于低剂量组,差异有统计学意义(P<0.05)。治疗后4、12、24周两组改良Kupperman评分均低于治疗前,差异有统计学意义(P<0.05);两组治疗后4、12、24周改良Kupperman评分比较,差异无统计学意义(P>0.05)。治疗前,两组子宫内膜厚度比较,差异无统计学意义(P>0.05);治疗后24周,低剂量组患者子宫内膜厚度显著厚于超低剂量组,差异有统计学意义(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论低剂量和超低剂量用药能改善围绝经期和绝经后期的临床症状及对激素水平的影响,但相较于低剂量水平,超低剂量水平优势更加明显,不良反应相对更低。Objective To explore the hormone levels and clinical effects of standardized hormone supplementation in perimenopausal and postmenopausal women.Methods Forty-eight perimenopausal women were treated with low-dose medication as the low-dose group;52 postmenopausal women during the same period were treated with ultra-low-dose medication as the ultra-low-dose group.The changes in hormone levels,menopausal-related symptom scores,endometrial thickness and the incidence of adverse reactions were compared between the two groups after administration.Results The levels of estradiol(E_(2))before treatment were(123.47±55.86)pmol/L and(70.14±33.16)pmol/L in low-dose group and ultra-low-dose group,respectively,and the difference was statistically significant(P<0.05).At 24 weeks after treatment,there was no significant difference in E_(2) levels between the two groups(P>0.05).After treatment,the level of follicle stimulating hormone(FSH)in ultra-low dose group was significantly lower than that in low-dose group,with statistical significance(P<0.05).At 4,12 and 24 weeks after treatment,the improved Kupperman score in both groups was lower than before treatment,and the difference was statistically significant(P<0.05).There was no significant difference in improved Kupperman score between the two groups at 4,12 and 24 weeks after treatment(P>0.05).Before treatment,there was no significant difference in endometrial thickness between 2 groups(P>0.05).24 weeks after treatment,endometrial thickness in low-dose group was significantly thicker than that in ultra-low dose group,with statistical significance(P<0.05).There was no statistical significance in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Low-dose and ultra-low-dose medication can improve the clinical symptoms of perimenopausal and post-menopausal periods and the effect on hormone levels,but compared with low-dose levels,ultra-low-dose levels have more obvious advantages and relatively lower adverse reactions.

关 键 词：围绝经期 绝经后 规范化激素补充治疗 不同剂量 

分 类 号：R711.75[医药卫生—妇产科学]